Asset Details
Do you wish to reserve the book?
Advances in small molecule inhibitors for treatment of psoriasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Advances in small molecule inhibitors for treatment of psoriasis
Do you wish to request the book?
Advances in small molecule inhibitors for treatment of psoriasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Advances in small molecule inhibitors for treatment of psoriasis
2021
Overview
[...]small molecule inhibitors (SMIs) have gained considerable attention among researchers, owing to the simplified synthesis processes, low-cost production, and the possibility of oral or topical administration. [14] Upper respiratory tract infections, nasopharyngitis, and headache were the most common AEs, and there was an increased risk of herpes zoster, serious infections, including tuberculosis, pneumonia, and influenza, as well as laboratory abnormalities in the tofacitinib treatment group. [...]routine laboratory monitoring is necessary when tofacitinib is prescribed in clinical settings. [...]tofacitinib has not received approval for the treatment of plaque psoriasis. [19] Upper respiratory tract infections and herpes zoster infection were reported to be the treatment-related AEs. Because the earlier pan-JAK inhibitor is relatively non-specific and has a high prevalence of AEs, selective TYK2 inhibitors have been developed.
Publisher
Lippincott Williams & Wilkins,Lippincott Williams & Wilkins Ovid Technologies,Wolters Kluwer
Subject
